Treating hearing loss with sound. There's a phrase in Russian: klin klinom, driving a wedge out with a wedge. The problem itself becomes the cure. I'm not a scientist. But I believe there's a certain elegance in solutions that use the nature of the problem to fix it. That belief led me to this hypothesis. When I shared our computational work with one of the world's leading STRC researchers, he called it the right direction and asked me to share the analysis with his team.
The idea: every gene therapy vector needs a promoter, a switch that controls when the cell makes the protein. Standard approach is always-on. Our hypothesis: put the gene behind a switch that responds to sound. Hair cells already have this machinery. Sound bends stereocilia, calcium rushes in, a chain reaction follows. We hijack it. Sound in = gene on. Silence = gene off. The child wears the hearing aid he already has. No special frequencies. Just everyday sounds, amplified to 60-80 dB.
Does the protein vanish at night? No. Stereocilin has a half-life of about 30 days (hair cells don't divide). It takes roughly 13 hours of hearing aid use to reach 50% of normal levels. After 72 hours, more than enough. Sleep doesn't reset anything. Even a week off barely makes a dent.
This is a computational hypothesis. Each individual component is proven (NFAT promoters, MET channel biophysics, mini-STRC packaging). Nobody has combined them for inner ear gene therapy yet.
We built a 5-variable ordinary differential equation (ODE) model to test whether the signaling cascade from sound to stereocilin production is quantitatively plausible. All parameters from peer-reviewed literature. The model simulates 72 hours across four scenarios.
With a realistic hearing aid schedule (16 hours ON at 70 dB, 8 hours sleep), the model predicts 29,571 stereocilin molecules per OHC after 72 hours (target: 15,000). In silence, only 1,023 molecules accumulate (6.8%). This gives a 29-fold dynamic range between sound-activated and silent states. The 50% therapeutic threshold is reached in just 13 hours of hearing aid use. The system self-regulates: protein saturates at the available binding sites on stereocilia, preventing overexpression.
| Parameter | Value | Source |
|---|---|---|
| MET channel conductance | 150 pS | Beurg et al. 2006 |
| Channels per bundle | 134 | Fettiplace 2017 |
| Endolymphatic potential | +80 mV | Standard |
| Calcineurin Kd (Ca²⁺) | 500 nM | Stemmer & Klee 1994 |
| NFAT nuclear import t½ | ~2 min | Tomida et al. 2003 |
| Promoter fold induction | up to 62x | Wu et al. 2023 |
| Promoter leakage | Zero (3 weeks) | Wu et al. 2023 |
| Apical compartment volume | 0.05 pL | Lumpkin & Bhatt 2001 |
Each parameter varied ±50% from baseline. Sensitivity index = (high - low) / baseline. Higher = model more sensitive to this parameter.
Transcription rate and translation rate have the highest sensitivity (1.50). This means accurate promoter characterization in hair cells is the most important experimental measurement needed to validate the model.
AlphaFold 3 Job 8 (NFATC1 + Calcineurin A + Calcineurin B) validates the signaling cascade used in the ODE model. The trimeric complex predicted with ipTM = 0.73 and ranking score 0.95:
NFAT regulatory domain is intrinsically disordered (chain_ptm 0.13), but becomes ordered upon binding calcineurin (chain_iptm 0.76). This disorder-to-order transition is the molecular switch that makes the 6xNFAT promoter work: only when Ca²⁺ activates calcineurin does NFAT adopt the conformation needed for nuclear import.
The complete ODE model is available as a Python script. Dependencies: numpy, scipy. Run it yourself to reproduce these results or modify parameters.
View on GitHub: ode_model.py